| Nome |
# |
|
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens., file e27ce42e-c849-2581-e053-d805fe0acbaa
|
2.814
|
|
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial, file e27ce42a-9a18-2581-e053-d805fe0acbaa
|
1.962
|
|
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer, file e27ce430-1013-2581-e053-d805fe0acbaa
|
1.087
|
|
MET signalling: principles and functions in development, organ regeneration and cancer., file e27ce426-cb2c-2581-e053-d805fe0acbaa
|
963
|
|
Adaptive mutability of colorectal cancers in response to targeted therapies, file e27ce42e-f361-2581-e053-d805fe0acbaa
|
871
|
|
Met-driven invasive growth involves transcriptional regulation of Arhgap12, file e27ce426-b6ca-2581-e053-d805fe0acbaa
|
775
|
|
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype, file e27ce430-1c84-2581-e053-d805fe0acbaa
|
475
|
|
MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases., file e27ce426-f87c-2581-e053-d805fe0acbaa
|
445
|
|
Stromal contribution to the colorectal cancer transcriptome., file e27ce427-4f59-2581-e053-d805fe0acbaa
|
408
|
|
Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer, file e27ce42b-b6f8-2581-e053-d805fe0acbaa
|
371
|
|
Genome-wide CRISPR screens reveal Hippo pathway activation as a resistance mechanism in BRAF mutant colon cancer, file f1b87298-ac36-415d-a66a-31ba34144357
|
362
|
|
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer, file e27ce42e-fdba-2581-e053-d805fe0acbaa
|
361
|
|
Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer, file e27ce431-af5f-2581-e053-d805fe0acbaa
|
294
|
|
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts, file e27ce42c-7d72-2581-e053-d805fe0acbaa
|
260
|
|
Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling, file e27ce432-2d9d-2581-e053-d805fe0acbaa
|
212
|
|
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, file e27ce428-9706-2581-e053-d805fe0acbaa
|
204
|
|
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors, file e27ce42a-cc29-2581-e053-d805fe0acbaa
|
199
|
|
Semalytics: a semantic analytics platform for the exploration of distributed and heterogeneous cancer data in translational research, file e27ce42e-a91c-2581-e053-d805fe0acbaa
|
178
|
|
Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals, file e27ce428-98ff-2581-e053-d805fe0acbaa
|
177
|
|
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases, file e27ce42e-676d-2581-e053-d805fe0acbaa
|
173
|
|
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice., file e27ce426-c9f8-2581-e053-d805fe0acbaa
|
169
|
|
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer, file e27ce426-de44-2581-e053-d805fe0acbaa
|
165
|
|
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers, file e27ce428-9c1b-2581-e053-d805fe0acbaa
|
162
|
|
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies., file e27ce428-9ce4-2581-e053-d805fe0acbaa
|
153
|
|
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models, file e27ce42e-c6ae-2581-e053-d805fe0acbaa
|
153
|
|
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity, file e27ce429-5269-2581-e053-d805fe0acbaa
|
152
|
|
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors., file e27ce426-fc01-2581-e053-d805fe0acbaa
|
151
|
|
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga, file e27ce42e-e46c-2581-e053-d805fe0acbaa
|
150
|
|
A diphtheria toxin resistance marker for in vitro and in vivo selection of stably transduced human cells, file e27ce427-ab32-2581-e053-d805fe0acbaa
|
149
|
|
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS, file e27ce426-d43e-2581-e053-d805fe0acbaa
|
144
|
|
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models., file e27ce427-0f27-2581-e053-d805fe0acbaa
|
134
|
|
Effective drug combinations in breast, colon and pancreatic cancer cells, file e27ce434-ce2d-2581-e053-d805fe0acbaa
|
119
|
|
One tool to find them all: A case of data integration and querying in a distributed LIMS platform, file e27ce42d-cfdb-2581-e053-d805fe0acbaa
|
116
|
|
Evolving neoantigen profiles in colorectal cancers with DNA repair defects, file e27ce42e-a91a-2581-e053-d805fe0acbaa
|
105
|
|
Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin, file f2b24279-fa11-4a36-8d9a-4ff4095de556
|
95
|
|
The genomic landscape of response to EGFR blockade in colorectal cancer, file e27ce428-9746-2581-e053-d805fe0acbaa
|
89
|
|
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer, file e27ce42f-ed2c-2581-e053-d805fe0acbaa
|
88
|
|
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts, file e27ce431-0751-2581-e053-d805fe0acbaa
|
80
|
|
Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathological correlations, file e27ce426-c2f8-2581-e053-d805fe0acbaa
|
68
|
|
Implementing systems modelling and molecular imaging to predict the efficacy of BCL-2 inhibition in colorectal cancer patient-derived xenograft models, file e27ce431-8d75-2581-e053-d805fe0acbaa
|
67
|
|
Synthetic lethality screening highlights colorectal cancer vulnerability to concomitant blockade of nedd8 and egfr pathways, file e27ce432-6e6c-2581-e053-d805fe0acbaa
|
59
|
|
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients, file e27ce426-f87f-2581-e053-d805fe0acbaa
|
57
|
|
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer, file e27ce428-a0b7-2581-e053-d805fe0acbaa
|
57
|
|
Only a subset of Met-activated pathways are required to sustain oncogene addiction, file e27ce426-c444-2581-e053-d805fe0acbaa
|
56
|
|
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3., file e27ce426-f670-2581-e053-d805fe0acbaa
|
54
|
|
The tetraspanin CD151 is required for met-dependent signaling and tumor cell growth, file e27ce426-cb47-2581-e053-d805fe0acbaa
|
51
|
|
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected, file e27ce42c-534d-2581-e053-d805fe0acbaa
|
50
|
|
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer, file e27ce42a-bea3-2581-e053-d805fe0acbaa
|
48
|
|
NOTCH3 SIGNALING REGULATES MUSASHI-1 EXPRESSION IN METASTATIC COLORECTAL CANCER CELLS., file e27ce426-f880-2581-e053-d805fe0acbaa
|
44
|
|
Inhibition of Src impairs the growth of met-addicted gastric tumors., file e27ce426-ca70-2581-e053-d805fe0acbaa
|
43
|
|
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer, file e27ce42b-0741-2581-e053-d805fe0acbaa
|
42
|
|
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas., file e27ce426-fc4a-2581-e053-d805fe0acbaa
|
41
|
|
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs., file e27ce427-0ec5-2581-e053-d805fe0acbaa
|
40
|
|
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer., file e27ce426-cf0f-2581-e053-d805fe0acbaa
|
39
|
|
Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma, file e27ce426-b9f0-2581-e053-d805fe0acbaa
|
37
|
|
MET SIGNALING REGULATES GROWTH, REPOPULATING POTENTIAL AND BASAL CELL-FATE COMMITMENT OF MAMMARY LUMINAL PROGENITORS: IMPLICATIONS FOR BASAL-LIKE BREAST CANCER., file e27ce427-0dc7-2581-e053-d805fe0acbaa
|
33
|
|
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas, file e27ce428-973d-2581-e053-d805fe0acbaa
|
33
|
|
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors., file e27ce426-cf12-2581-e053-d805fe0acbaa
|
30
|
|
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer., file e27ce426-e096-2581-e053-d805fe0acbaa
|
22
|
|
PDX-MI: Minimal information for patient-derived tumor xenograft models, file e27ce42c-9a63-2581-e053-d805fe0acbaa
|
22
|
|
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells, file eddce5b7-5d9a-414e-811a-e6a359372a96
|
22
|
|
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells, file 0680489c-fa68-4090-80fb-bcf874f958a2
|
21
|
|
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer, file e27ce42d-8306-2581-e053-d805fe0acbaa
|
20
|
|
Multi-label transcriptional classification of colorectal cancer reflects tumor cell population heterogeneity, file e8bd37d5-969c-4ca3-abe2-6d1e7c8b1c15
|
17
|
|
The EurOPDX Data Portal: an open platform for patient-derived cancer xenograft data sharing and visualization, file 021fdce9-fe2b-479d-8252-f176a6116ab2
|
16
|
|
A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy, file e27ce433-9c89-2581-e053-d805fe0acbaa
|
16
|
|
EGAsubmitter: A software to automate submission of nucleic acid sequencing data to the European Genome-phenome Archive, file 6be964fe-555a-4cc8-aad8-67a1f04e470f
|
10
|
|
CONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system, file 67263b77-3138-4f87-ac55-03cc2fceba76
|
9
|
|
Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer, file 75e3d6c4-7503-47c3-a4e2-b14d549d6a65
|
9
|
|
Adaptive mutability of colorectal cancers in response to targeted therapies, file e27ce42e-f362-2581-e053-d805fe0acbaa
|
8
|
|
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts, file e27ce431-0557-2581-e053-d805fe0acbaa
|
8
|
|
Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer, file a0e8a7d8-c14b-4fbf-862b-54e52dc606bf
|
7
|
|
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts, file 52c30ba5-92de-4264-8774-48ec22157379
|
5
|
|
Stromal contribution to the colorectal cancer transcriptome., file e27ce426-9d30-2581-e053-d805fe0acbaa
|
5
|
|
A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy, file e27ce42c-75e6-2581-e053-d805fe0acbaa
|
5
|
|
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT), file 106a6aac-a35e-4286-a00d-8cde54a95bd1
|
4
|
|
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies., file e27ce426-9d2c-2581-e053-d805fe0acbaa
|
4
|
|
PhyliCS: a Python library to explore scCNA data and quantify spatial tumor heterogeneity, file 3a2dac88-4d55-4fff-966f-06a7f5a06d55
|
3
|
|
Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer, file d7250c76-5d9e-47fb-9c4d-d8fb5de802ca
|
3
|
|
Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: Six degrees of separation, file e27ce426-eea8-2581-e053-d805fe0acbaa
|
3
|
|
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment, file e27ce427-4ee1-2581-e053-d805fe0acbaa
|
3
|
|
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial, file e27ce42a-9a17-2581-e053-d805fe0acbaa
|
3
|
|
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer, file e27ce42a-e1bf-2581-e053-d805fe0acbaa
|
3
|
|
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected, file e27ce42d-e27a-2581-e053-d805fe0acbaa
|
3
|
|
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, file e27ce432-5371-2581-e053-d805fe0acbaa
|
3
|
|
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3., file e27ce426-f66e-2581-e053-d805fe0acbaa
|
2
|
|
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas., file e27ce426-fc49-2581-e053-d805fe0acbaa
|
2
|
|
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas, file e27ce428-a1a3-2581-e053-d805fe0acbaa
|
2
|
|
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer, file e27ce432-5370-2581-e053-d805fe0acbaa
|
2
|
|
Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling, file e27ce435-20b9-2581-e053-d805fe0acbaa
|
2
|
|
Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma, file e27ce426-b9ef-2581-e053-d805fe0acbaa
|
1
|
|
Only a subset of Met-activated pathways are required to sustain oncogene addiction, file e27ce426-c443-2581-e053-d805fe0acbaa
|
1
|
|
Inhibition of Src impairs the growth of met-addicted gastric tumors., file e27ce426-ca6f-2581-e053-d805fe0acbaa
|
1
|
|
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition., file e27ce426-ca71-2581-e053-d805fe0acbaa
|
1
|
|
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer., file e27ce426-cf0e-2581-e053-d805fe0acbaa
|
1
|
|
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer, file e27ce426-de43-2581-e053-d805fe0acbaa
|
1
|
|
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients, file e27ce426-f87d-2581-e053-d805fe0acbaa
|
1
|
|
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs., file e27ce427-0ec4-2581-e053-d805fe0acbaa
|
1
|
|
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, file e27ce428-9900-2581-e053-d805fe0acbaa
|
1
|
|
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer, file e27ce428-a0ae-2581-e053-d805fe0acbaa
|
1
|
| Totale |
16.188 |